{
  "disease_name": "Prostate cancer",
  "synonyms": [],
  "summary": "Prostate cancer is a type of cancer that occurs in the prostate, a gland in the male reproductive system. It is one of the most common cancers in men and often grows slowly, but can sometimes grow quickly and spread to other parts of the body, making it serious.",
  "causes": [
    "Accumulation of genetic mutations in prostate cells",
    "Changes in DNA",
    "Inherited genetic changes",
    "Gene fusion between TMPRSS2 and ERG",
    "Mutations disabling SPOP",
    "Hyperactivation of FOXA1",
    "Defective DNA damage repair genes (e.g., p53, RB1, BRCA2, ATM)",
    "Aberrant activation of the Wnt signaling pathway",
    "Dysregulation of the PI3K pathway"
  ],
  "risk_factors": [
    "Increasing age",
    "Family history of prostate cancer",
    "African American or African-Caribbean ancestry",
    "Obesity",
    "High blood cholesterol levels",
    "Chronic inflammation",
    "Dietary factors (high dietary fats, polycyclic aromatic hydrocarbons, calcium)",
    "Taller height"
  ],
  "symptoms": [
    "Erectile dysfunction",
    "Blood in urine",
    "Blood in semen",
    "Trouble urinating (frequent urination, slow or weak urine stream)",
    "Pain or burning when urinating",
    "Pain in lower back, hips, or pelvis",
    "Painful ejaculation",
    "Fatigue",
    "Unexplained weight loss",
    "Back or bone pain",
    "Leg weakness or paralysis",
    "Bone fracture"
  ],
  "diagnosis": [
    "Digital rectal examination (DRE)",
    "Prostate-specific antigen (PSA) blood test",
    "Imaging tests (ultrasound, MRI, CT scans, PSMA scan, bone scintigraphy)",
    "Prostate biopsy",
    "Histopathologic examination of biopsy tissue",
    "Gleason grading system",
    "TNM staging system",
    "Cambridge Prognostic Group system"
  ],
  "treatments": [
    "Active surveillance",
    "Watchful waiting",
    "Radical prostatectomy (surgery to remove the prostate)",
    "Radiation therapy (intensity-modulated radiation therapy, brachytherapy, external beam radiotherapy)",
    "Hormone therapy (androgen deprivation therapy)",
    "Chemotherapy (docetaxel, cabazitaxel, mitoxantrone)",
    "Targeted therapy (e.g., Lu-177 PSMA, PARP inhibitors, immune checkpoint inhibitors)",
    "Immunotherapy (Sipuleucel-T, pembrolizumab)",
    "Supportive care (pain management, treatment for lymphedema, psychological interventions)",
    "Bone modifying agents (zoledronic acid, denosumab)",
    "Steroids"
  ],
  "related_genes": [
    "BRCA2",
    "HOXB13",
    "BRCA1",
    "ATM",
    "NBS1",
    "MSH2",
    "MSH6",
    "PMS2",
    "CHEK2",
    "RAD51D",
    "PALB2",
    "MYC",
    "TMPRSS2",
    "ERG",
    "SPOP",
    "FOXA1",
    "p53",
    "RB1",
    "PTEN",
    "APC",
    "CTNNB1",
    "PI3KCA",
    "PI3KCB",
    "AKT1",
    "Androgen receptor",
    "CYP3A4",
    "CYP17"
  ],
  "subtypes": [
    "Castration-resistant prostate cancer (CRPC)",
    "Castration-sensitive prostate cancer"
  ]
}